Patent ID: 8252789

Claim:
A method for treating a lipid storage disease in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula 1b: wherein each instance of R a is independently C 1-6 alkyl-amino, di(C 1-6 alkyl)amino, substituted C 1-6 alkyl-amino, di(substituted C 1-6 alkyl)amino, C 3-6 alkenyl-amino, di(C 3-6 alkenyl)amino, substituted C 3-6 alkenyl-amino, or di(substituted C 3-6 alkenyl)amino; and R b is HO—C 1-6 alkyl-C 2-6 alkenyl, R 7 -O—C 1-6 alkyl -C 2-6 alkenyl, R 7 NH—C 1-6 alkyl-C 2-6 alkenyl, R 6 R 7 N—C 1-6 alkyl-C 2-6 alkenyl, R 7 NH—C(O)—O—C 1-6 alkyl-C 2-6 alkenyl, R 7 O—C(O)—O—C 1-6 alkyl-C 2-6 alkenyl, or R 7 O—C(O)—O—C 1-6 alkyl-C 2-6 alkenyl; wherein R 6 and R 7 are independently selected from the group consisting of C 1-6 alkyl, phenyl-C 1-6 alkyl, C 1-6 alkoxycarbonylmethyleneoxy, hydroxy-C 2-6 alkyl, C 1-6 alkyloxy-C 2-6 alkyl, amino-C 2-6 alkyl, C 1-6 alkylamino-C 2-6 alkyl, di(C 1-6 alkyl)amino-C 2-6 alkyl, C 1-6 alkylthio-C 2-6 alkyl, substituted C 1-6 alkoxy-C 2-6 alkyl, substituted C 1-6 alkylamino-C 2-6 alkyl, di(substituted C 1-6 alkyl)amino-C 2-6 alkyl, substituted C 1-6 alkylthio-C 2-6 alkyl, wherein the substituents are selected from the group consisting of pyrrolidino, piperidino, morpholino, piperazino, 4-N—C 1-6 alkylpiperazino, 4-N-C 3-6 alkenylpiperazino, 4-N-(C 1-6 alkoxy C 1-6 alkyl)piperazino, 4-N—(C alkoxy-C 3-6 alkenyl)piperazino, 4-N—(C 1-6 alkylamino-C 1-6 alkyl)piperazino, 4-N—(C 1-6 alkylamino-C 3-6 alkenyl)piperazino, imidazolyl, oxazolyl, and thiazolyl; and R 4 is selected from the group consisting of hydrogen; (i) hydrogen (ii) substituted C 1-11 alkyl or C 2-11 alkenyl wherein the substituents are independently selected from the group consisting of: (a) hydrogen, hydroxy, C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkylamino, phenyl-C 1-6 alkylamino, or C 1-6 alkoxycarbonyl; (b) substituted C 1-6 alkyloxy, C 3-6 alkenyloxy, or substituted C 3-6 alkenyloxy; (c) di(C 1-6 alkyl)amino, substituted C 1-6 alkyl-amino, di(substituted C 1-6 alkyl)amino, C 3-6 alkenyl-amino, di(C 3-6 alkenyl)amino, substituted C 3-6 alkenyl-amino, or di(substituted C 3-6 alkenyl)amino; and (d) pyrrolidino, piperidino, morpholino, imidazolyl, substituted imidazolyl, piperazino, 4-N—C 1-6 alkylpiperazino, 4-N—C 3-6 alkenylpiperazino, 4-N—(C 1-6 alkoxy C 1-6 alkyl)piperazino, 4-N—(C 1-6 alkoxy C 3-6 alkenyl)piperazino, 4-N—(C 1-6 alkylamino C 1-6 alkyl)piperazino, or 4-N—(C 1-6 alkylamino C 3-6 alkenyl)piperazino; and (iii) aryl C 0-11 alkyl wherein the aryl group is selected from phenyl, imidazolyl, furyl, and thienyl, wherein the disease is Fabry's disease.